Name | Pramocaine hydrochloride |
Description | Pramocaine hydrochloride (Pramoxine HCl), a topical anesthetic, is served as an antipruritic. |
In vitro | When administered to canines exhibiting dyspnea (breathing difficulty) and tremors, Pramoxine elicited specific changes in skin temperature at which the activation and suppression of panting and shivering occur. These changes are thought to be mediated by peripheral nerves that control the terminal mechanisms of thermoregulation. In studies on guinea pig ileum, Pramoxine (1.7 mM) demonstrated a lesser reduction in response to Substance P compared to its effects on responses to acetylcholine, BaCl2, and histamine. Pramoxine has been identified as having anesthetic inhibitory potency, with a pKa of 6.4 in guinea pig ileum. |
In vivo | Pramoxine is frequently used in conjunction with Hydrocortisone, Colloidal oatmeal, Menthol, and Petrolatum. |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Solubility Information | DMSO : 75 mg/mL (227.37 mM)
|
Keywords | Pramocaine | Pramoxine | Pramocaine hydrochloride | Pramoxine Hydrochloride | Inhibitor | inhibit | Pramocaine Hydrochloride |
Inhibitors Related | Phenytoin sodium | Lidocaine | Valproic Acid | Lidocaine hydrochloride | L-Aspartic aicd sodium | Mebeverine hydrochloride | Amitriptyline hydrochloride | Riluzole | Benzocaine | Nefopam hydrochloride |
Related Compound Libraries | Bioactive Compound Library | Pain-Related Compound Library | Membrane Protein-targeted Compound Library | Drug Repurposing Compound Library | Anti-Cancer Approved Drug Library | FDA-Approved Drug Library | Cosmetic Ingredient Compound Library | Bioactive Compounds Library Max | Ion Channel Targeted Library | Anti-Cancer Drug Library |